| |||
| Combination of | |||
|---|---|---|---|
| Tegafur | Antineoplastic agent | ||
| Uracil | Nucleobase | ||
| Clinical data | |||
| Trade names | Uftoral, others | ||
| Identifiers | |||
| CAS Number | |||
| PubChem CID | |||
| DrugBank | |||
| UNII | |||
Tegafur/uracil (abbreviation: UFT[1]) is a chemotherapy drug combination used in the treatment of cancer, primarily bowel cancer.
UFT is an oral formulation combining uracil (a competitive inhibitor of dihydropyrimidine dehydrogenase), and tegafur (a bioavailable 5-fluorouracil (5-FU) prodrug) in a 4:1 molar ratio.[1]
Uracil has also been stated to help protect the gastrointestinal tract from 5-FU toxicity and the related metabolites, with less side effects than 5-FU and other 5-FU related (pro)drugs.[citation needed]
- ^ a b "Tegafur-uracil". NCI dictionaries. National Cancer Institute, U.S. Department of Health and Human Services. 2011-02-02. Retrieved 2024-06-20.